

# COVAX UPDATE

BOARD MEETING

**Derrick Sim**

6-7 December 2023, Accra, Ghana

# COVAX has made considerable achievements to date



## *COVID-19 coverage*

- **57%** coverage with complete primary series among AMC participants
  - **17%** coverage with booster dose
- Only **6** countries remain under 10% coverage



## *Health care workers*

- **84%** vaccinated with the complete primary series
  - **57%** reached with a booster dose



## *Older adults*

- **72%** vaccinated with the complete primary series
  - **24%** reached with a booster dose




## *COVID-19 impact*

As of end 2022, estimated **2.7 million** deaths averted due to COVAX-supported doses among AMC participants



# COVAX deliveries 2021-2023




\* Includes doses formally allocated but pending country acceptance by in-country delivery

**1.97bn COVAX doses have been delivered to 146 countries, with 1.76bn doses to 87 COVAX AMCs**

## 2023 COVID-19 emergency phase over, which reduces vaccine demand:

1. The lifting of the PHEIC in May 2023 - impacting perception of risk
2. Updated SAGE guidance on priority groups
3. Shift from campaigns to routine programmes leading to slowing of absorption

# Of the total US\$ 1.6 billion funding mobilised for COVID-19 delivery, 92% has been committed



- CDS3 Funding window closed in June 2023
  - A total of US\$ 603 million CDS3 Funding was awarded to 81 AMC participants
  - US\$ 30 million was awarded for emergency CDS funding needs across 12 country requests
- Over 50% of CDS3 funding was programmed towards integration of COVID-19 and Routine Immunisation (RI) activities
- Countries have reported positive impacts on strengthening health systems, and mainly linked to:
  - Upscaling cold chain infrastructure
  - Improving digitisation of health data
  - Strengthening demand creation and community engagement
  - Creating COVID-19 and RI integrated delivery opportunities

# Update on 2024-2025 COVID-19 vaccine programme

## Core objectives

- Continued support for high priority user groups per the SAGE Roadmap
- Continued HSS and C19 integration support, including catch-up activities

## Applications

- **An independent review panel approved 16 / 17 Wave 1 applications for a total of 20 million doses in Sep 2023**
- Wave 2 independent review panel to be held in Dec 2023
- Eligible countries include Gavi54 + AMC37

## Supply and demand

- **Supply:** Multi-source supply strategy w/tendered doses, APA spillover and donated doses
  - Results of UNICEF tender expected has been delayed, but are expected imminently
- **Demand:** HLRP has approved 60 million COVID-19 doses for AMC91 countries in 2024
  - Option to increase global envelope pending results of the Wave 2 applications in Dec 2023

## Continued CDS support

- Countries can reallocate their approved CDS funding and programme towards delivery support for 2024 and 2025
- Contingency fund of US\$ 20 million available to support eligible countries that may require additional CDS funding if there are gaps in funding following the reallocation of existing CDS funds
- Health system strengthening cross-cutting CDS support to continue until 2025

## Risks

- Continued evolution of COVID-19
  - Ongoing uncertainty in Vaccine demand
  - Reduced tracking, sequencing and reporting to WHO
- Potential mismatch in country product preferences and available supply

# Taking COVAX key learnings forward

## COVAX learnings incorporated in Gavi PPPR approach



Start planning and preparations for future pandemics now



Include broader group of partners [regional groups, country implementors, CSOs] in future design and implementation for PPPR



Secure earlier and greater access to at-risk / contingency financing for both procurement and vaccine delivery



Diversify vaccine manufacturing



Further enhance efforts towards building resilient health systems

## COVAX learnings incorporated into Gavi 5.1 and consider for Gavi 6.0 development



Improving access to vaccines in complex humanitarian settings



Building stronger partnerships with humanitarian agencies



New process adaptations (e.g. EVOLVE, expediting disbursements to countries, building on the COVAX Collaboration Platform (CCP))



Adoption of “must-wins” to unite leadership on top priorities

**Sincere thanks to all who have  
contributed to COVAX and its efforts**